ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
122.098,09
-0,50%
S&P 500
5.277,51
0,80%
US Dollar vs BRL
5,2463
0,01%
Bitcoin
67.588,22
0,16%
Brent Oil
81,295
0,00%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Oasmia Pharmaceuticals AB (OASM)

  7. Oasmia Pharmaceuticals AB (OASM) Notícias

OASM

Oasmia Pharmaceuticals AB (OASM)

Oasmia Pharmaceuticals AB
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:OASM
DataHoraFonteTítuloCódigoCompanhia
07/03/202210:35Business WireCORRECTING and REPLACING Whiting and Oasis to Combine in $6.0 Billion Merger of Equals TransactionNASDAQ:OASMOasmia Pharmaceuticals AB
07/03/202209:20Business WireWhiting and Oasis to Combine in $6.0 Billion Merger of Equals TransactionNASDAQ:OASMOasmia Pharmaceuticals AB
27/11/201911:54Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:OASMOasmia Pharmaceuticals AB
21/11/201911:41Edgar (US Regulatory)Post-effective Amendment to a Previously Filed F-6. (f-6 Pos)NASDAQ:OASMOasmia Pharmaceuticals AB
23/08/201909:01Edgar (US Regulatory)Notice of Termination of a Foreign Private Issuer's Registration of a Class of Securities Under Section 12(b) (15f-12b)NASDAQ:OASMOasmia Pharmaceuticals AB
21/08/201917:06Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:OASMOasmia Pharmaceuticals AB
13/08/201907:03Edgar (US Regulatory)Notification Filed by a National Securities Exchange to Report the Removal From Listing and Registration of Matured , Redeeme...NASDAQ:OASMOasmia Pharmaceuticals AB
13/08/201907:00Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:OASMOasmia Pharmaceuticals AB
08/08/201917:15Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:OASMOasmia Pharmaceuticals AB
20/11/201805:00GlobeNewswire Inc.New U.S. patent related to Oasmia Pharmaceutical’s nanotechnology platform XR17 has been grantedNASDAQ:OASMOasmia Pharmaceuticals AB
03/10/201804:00GlobeNewswire Inc.Oasmia Presents Positive Efficacy and Safety Data for Doxophos Vet in Treatment of Naïve Dogs with LymphomaNASDAQ:OASMOasmia Pharmaceuticals AB
21/09/201804:20GlobeNewswire Inc.Oasmia Pharmaceutical Receives Positive CHMP Opinion for Apealea® (paclitaxel micellar) in the European UnionNASDAQ:OASMOasmia Pharmaceuticals AB
14/09/201817:13Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:OASMOasmia Pharmaceuticals AB
31/08/201817:09Edgar (US Regulatory)Notification That Form 20-f Will Be Submitted Late (nt 20-f)NASDAQ:OASMOasmia Pharmaceuticals AB
18/05/201817:09Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-3/a)NASDAQ:OASMOasmia Pharmaceuticals AB
30/04/201817:19Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-3)NASDAQ:OASMOasmia Pharmaceuticals AB
11/04/201817:07Edgar (US Regulatory)Amended Annual and Transition Report (foreign Private Issuer) (20-f/a)NASDAQ:OASMOasmia Pharmaceuticals AB
14/02/201812:41Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:OASMOasmia Pharmaceuticals AB
01/11/201717:24Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:OASMOasmia Pharmaceuticals AB
08/08/201708:00GlobeNewswire Inc.Oasmia Pharmaceutical receives market approval for its Anti-Cancer Drug Doxophos® in RussiaNASDAQ:OASMOasmia Pharmaceuticals AB
14/06/201708:00GlobeNewswire Inc.Oasmia Pharmaceutical enters into new exclusive marketing and distribution agreement concerning Russia and other CIS marketsNASDAQ:OASMOasmia Pharmaceuticals AB
13/02/201719:39Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:OASMOasmia Pharmaceuticals AB
23/01/201710:00GlobeNewswire Inc.Oasmia Pharmaceutical Announces Strategic Move to Bolster Efforts for its Veterinary DivisionNASDAQ:OASMOasmia Pharmaceuticals AB
09/01/201718:22Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:OASMOasmia Pharmaceuticals AB
21/12/201610:00GlobeNewswire Inc.Oasmia Pharmaceutical Reports Positive Results from Study on Weekly Administration of Apealea® (Paclical®)NASDAQ:OASMOasmia Pharmaceuticals AB
07/12/201612:30GlobeNewswire Inc.Oasmia Pharmaceutical AB’s Warrant Programs Fully SubscribedNASDAQ:OASMOasmia Pharmaceuticals AB
02/12/201613:05GlobeNewswire Inc.Interim report for the period May - October 2016NASDAQ:OASMOasmia Pharmaceuticals AB
22/11/201610:49GlobeNewswire Inc.Communiqué from Extraordinary General Meeting 2016NASDAQ:OASMOasmia Pharmaceuticals AB
02/11/201609:24GlobeNewswire Inc.Nexttobe Extends Loan to Oasmia PharmaceuticalNASDAQ:OASMOasmia Pharmaceuticals AB
01/11/201619:19GlobeNewswire Inc.Oasmia Pharmaceutical Announces Change in OwnershipNASDAQ:OASMOasmia Pharmaceuticals AB
 Apresentando as notícias mais relevantes sobre:NASDAQ:OASM

Seu Histórico Recente

USOTC
SEBC
Southeastern Banking (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados